ライフサイエンスコーパス: parainfluenza virus

1 rus, rhinovirus, and influenza virus but not parainfluenza virus.

2 tein subunits play the cell entry concert of parainfluenza viruses.

3 p of viruses that includes measles virus and parainfluenza viruses.

4 an respiratory syncytial virus and the human parainfluenza viruses.

5 detects influenza A virus (Flu-A) and Flu-B, parainfluenza virus 1 (PIV-1), PIV-2, and PIV-3, and res

6 l virus (RSV), human metapneumovirus (HMPV), parainfluenza virus 1 to 3 (PIV1, PIV2, and PIV3), and a

7 za A H3, influenza A H1N1/2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainflue

8 dated on human immunodeficiency virus, human parainfluenza virus 1-4, human metapneumovirus, human co

9 FilmArray RP detected more parainfluenza viruses 1 and 3 than ProParaflu+ (18 versu

10 virus, influenza A virus, influenza B virus, parainfluenza viruses 1 to 3, and respiratory syncytial

11 nfluenza A virus H1-2009, influenza B virus, parainfluenza viruses 1 to 4, respiratory syncytial viru

12 syncytial virus; influenza A and B viruses; parainfluenza viruses 1, 2, 3, and 4; human metapneumovi

13 an respiratory syncytial virus (HRSV); human parainfluenza viruses 1, 2, and 3 (HPIV1, -2, and -3, re

14 adenovirus, influenza A and B viruses, human parainfluenza viruses 1-3 (HPIV), respiratory syncytial

15 piratory syncytial virus, influenza A and B, parainfluenza viruses 1-3, and adenovirus.

16 picornaviruses, coronaviruses 229E and OC43, parainfluenza viruses 1-3, influenza viruses AH1, AH3, a

17 in reaction for respiratory syncytial virus, parainfluenza viruses 1-4, influenza A and B, human meta

18 hese are encoded by mumps virus (MuV), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5

19 Simian virus 5 (SV5) targets STAT1, human parainfluenza virus 2 targets STAT2, and mumps virus tar

20 N1/2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainflue

21 ith respiratory syncytial virus (RSV), human parainfluenza virus 3 (HPIV-3), and influenza virus on t

22 Human parainfluenza virus 3 (HPIV3) and respiratory syncytial

23 We previously reported that a human parainfluenza virus 3 (HPIV3) F peptide effectively inhi

24 titatively influence fusion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations

25 oviruses parainfluenza virus 5 (PIV5), human parainfluenza virus 3 (HPIV3), and respiratory syncytial

26 yxoviruses, such as Nipah virus (NiV), human parainfluenza virus 3 (HPIV3), measles virus (MeV), mump

27 Parainfluenza virus 3 (PIV-3) infection is highly restri

28 The majority of this decrease was in parainfluenza virus 3 (PIV3) (8.3% to 2.2%, P < .001).

29 c fibrosis patients; however, its use during parainfluenza virus 3 (PIV3) infection has not been eval

30 The secreted human parainfluenza virus 3 F forms a trimer with distinct hea

31 However, we found that a human parainfluenza virus 3 F-peptide is more effective at inh

32 eaved ectodomain of the paramyxovirus, human parainfluenza virus 3 fusion (F) protein, a member of th

33 homologous HN protein, as well as NDV-human parainfluenza virus 3 HN chimeras.

34 ection but similar to that for influenza and parainfluenza virus 3 infection in all age groups.

35 mumps virus, Newcastle disease virus, human parainfluenza virus 3, and Nipah virus.

36 arainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus

37 cell lines with Sendai virus (SeV) or human parainfluenza virus 3, two prototypic paramyxoviruses, c

38 the shape of the mRNA abundance gradient in parainfluenza virus 3, whereas a combination of this fac

39 dence similar to that of influenza virus and parainfluenza virus 3.

40 on of 274 of 279 influenza viruses, 33 of 38 parainfluenza viruses, 35 of 51 adenoviruses, and 52 of

41 Putative viral pathogens included human parainfluenza virus 4 (aOR 9.3, P = .12), human bocaviru

42 rus [EV], 118; bocavirus, 8; coronavirus, 7; parainfluenza virus 4, 4; Mycoplasma pneumoniae, 1).

43 arainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus/enterovirus, respirato

44 lture (metapneumovirus, coronaviruses [CoV], parainfluenza viruses 4a and 4b, and rhinoviruses) and t

45 hat Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix

46 Parainfluenza virus 5 (PIV5) activates and is neutralize

47 For the paramyxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP inter

48 Proline substitution in this region of HN of parainfluenza virus 5 (PIV5) and Newcastle disease virus

49 rmined the structure of the L-P complex from parainfluenza virus 5 (PIV5) at 4.3- angstrom resolution

50 In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/

51 The paramyxovirus parainfluenza virus 5 (PIV5) enters cells by fusion of t

52 igh similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural

53 Because only the prefusion structure of the parainfluenza virus 5 (PIV5) F-trimer is available, to s

54 MR spectroscopy, we show that the TMD of the parainfluenza virus 5 (PIV5) fusion protein adopts lipid

55 ucts were coexpressed with the nonhomologous parainfluenza virus 5 (PIV5) fusion protein, indicating

56 Parainfluenza virus 5 (PIV5) HN exists as a noncovalent

57 Parainfluenza virus 5 (PIV5) is a member of the Paramyxo

58 Parainfluenza virus 5 (PIV5) is a promising viral vector

59 Parainfluenza virus 5 (PIV5) is a prototypical paramyxov

60 Parainfluenza virus 5 (PIV5) is an appealing vector for

61 Parainfluenza virus 5 (PIV5) is an enveloped, single-str

62 The P protein of parainfluenza virus 5 (PIV5) is an essential cofactor of

63 Parainfluenza virus 5 (PIV5) is thought to contribute to

64 To investigate the role of NP protein in parainfluenza virus 5 (PIV5) particle formation, NP prot

65 ation of copyback DVGs readily occurs during parainfluenza virus 5 (PIV5) replication, but that their

66 In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glyco

67 serendipitously identified a viral mRNA from parainfluenza virus 5 (PIV5) that activates IFN expressi

68 Preparations of parainfluenza virus 5 (PIV5) that are potent activators

69 quence variation of 16 different isolates of parainfluenza virus 5 (PIV5) that were isolated from a n

70 unable to be recognized by measles virus and parainfluenza virus 5 (PIV5) V proteins were tested in s

71 We tested the recombinant parainfluenza virus 5 (PIV5) vectors expressing RSV glyc

72 he threonine residue at position 286 of P of parainfluenza virus 5 (PIV5) was found phosphorylated.

73 The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC u

74 rotein (prefusion form) of the paramyxovirus parainfluenza virus 5 (PIV5) WR isolate was determined.

75 Parainfluenza virus 5 (PIV5), a paramyxovirus, is not kn

76 Similar results were also observed with parainfluenza virus 5 (PIV5), a paramyxovirus, when neut

77 Here we show that vaccination with parainfluenza virus 5 (PIV5), a promising live viral vec

78 Infection by parainfluenza virus 5 (PIV5), a prototypical member of t

79 Parainfluenza virus 5 (PIV5), a prototypical paramyxovir

80 The genome of parainfluenza virus 5 (PIV5), a prototypical paramyxovir

81 V), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5 (PIV5), all members of the genus R

82 During the replication of parainfluenza virus 5 (PIV5), copyback defective virus g

83 Parainfluenza virus 5 (PIV5), formerly known as simian v

84 y, papaverine also inhibited paramyxoviruses parainfluenza virus 5 (PIV5), human parainfluenza virus

85 that a porcine isolate of the paramyxovirus parainfluenza virus 5 (PIV5), known as SER, requires a l

86 The strain diversity of a rubulavirus, parainfluenza virus 5 (PIV5), was investigated by compar

87 Previously, we developed two parainfluenza virus 5 (PIV5)-based RSV vaccine candidate

88 We previously generated a parainfluenza virus 5 (PIV5)-vectored vaccine candidate

89 In this study, we evaluated two parainfluenza virus 5 (PIV5)-vectored vaccines expressin

90 he FP of the F protein of the paramyxovirus, parainfluenza virus 5 (PIV5).

91 f the matrix (M) protein of a paramyxovirus, parainfluenza virus 5 (PIV5).

92 -3 as a binding partner for the M protein of parainfluenza virus 5 (PIV5).

93 Similar results were also observed with parainfluenza virus 5 (PIV5).

94 on (F) protein from the paramyxovirus simian parainfluenza virus 5 (SV5) resulted in mutant F protein

95 NASEK was dispensable for viruses, including parainfluenza virus 5 and Coxsackie B virus, that enter

96 ructed chimeras containing the ectodomain of parainfluenza virus 5 F (PIV5 F) and either the MPER, th

97 Here we report the crystal structure of the parainfluenza virus 5 F protein in its prefusion conform

98 ess the functional role of the paramyxovirus parainfluenza virus 5 F protein TM domain, alanine scann

99 Here, a soluble form of parainfluenza virus 5 F was triggered to refold using te

100 , we show that the FP from the paramyxovirus parainfluenza virus 5 fusogenic protein, F, forms an N-t

101 ng globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable

102 usion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of

103 Knockdown of IFIT1 restored parainfluenza virus 5 infection in IFN-alpha-pretreated,

104 By modeling the crystal structure of parainfluenza virus 5 into the density, it is shown that

105 The paramyxovirus parainfluenza virus 5 mediates membrane merger through i

106 t robust maturation following infection with parainfluenza virus 5 or influenza virus.

107 this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expr

108 ed "stalk exposure model" first proposed for parainfluenza virus 5 to other paramyxoviruses and propo

109 athogens: human respiratory syncytial virus, parainfluenza virus 5, and Sendai virus.

110 A parainfluenza virus 5-vectored vaccine expressing the na

111 1 (IFIT1) is the principal antiviral ISG for parainfluenza virus 5.

112 sequence, FPIV, important for the budding of parainfluenza virus 5.

113 recently published prefusogenic structure of parainfluenza virus 5/SV5 F places CBF(2) in direct cont

114 pproach is further demonstrated here for the parainfluenza virus, a virus which can be life threateni

115 or detecting respiratory viruses, especially parainfluenza virus and adenovirus.

116 d five in which the PLx-RVP failed to detect parainfluenza virus and one in which the detection of in

117 ow fever virus, Japanese encephalitis virus, parainfluenza virus and Sendai virus.

118 nimal pathogens, such as measles, mumps, and parainfluenza viruses and the deadly henipaviruses Nipah

119 ple viruses (respiratory syncytial virus and parainfluenza virus) and multiple phenotypes.

120 or respiratory syncytial virus, 83 sites for parainfluenza virus, and 65 sites for metapneumovirus.

121 tory syncytial virus, human metapneumovirus, parainfluenza virus, and influenza virus) by reverse-tra

122 nfluenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus are the most co

123 nfluenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus.

124 etapneumovirus, respiratory syncytial virus, parainfluenza viruses, and Haemophilus influenzae being

125 ly enriched rhinovirus, influenza virus, and parainfluenza viruses, and maintained the stoichiometric

126 Parainfluenza viruses are a common cause of seasonal res

127 Parainfluenza viruses are known to inhibit type I interf

128 causes of lower respiratory disease like the parainfluenza viruses, as well as agents of lethal encep

129 protein and nucleocapsid sustain assembly of parainfluenza viruses at the plasma membrane.

130 2 unit, with respiratory syncytial virus and parainfluenza virus being the most common viruses isolat

131 ke (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as

132 Three human parainfluenza viruses bind to glycans terminating with N

133 (RSV), adenoviruses, influenza viruses, and parainfluenza viruses by use of nested polymerase chain

134 Human parainfluenza viruses cause several serious respiratory

135 Although influenza and parainfluenza viruses commonly cause respiratory tract i

136 , which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and huma

137 canine adenovirus type 2 (CAV-2), and canine parainfluenza virus (CPIV), respiratory disease was ende

138 sociation with age; especially rhinovirus or parainfluenza virus detection showed positive associatio

139 Our results illustrate how the particles of parainfluenza viruses efficiently accommodate cargoes of

140 Parainfluenza viruses enter host cells by fusing the vir

141 Parainfluenza virus epidemics were found mostly in sprin

142 By comparison, parainfluenza virus had longer duration of epidemics (6.

143 V-respiratory syncytial virus (RSV) or human parainfluenza virus (HPIV) coinfections had wheezing tha

144 The human parainfluenza virus (hPIV) hemagglutinin-neuraminidase (

145 presence of the second binding site on human parainfluenza virus (hPIV) type 1, 2, and 3 and Sendai v

146 es, Respiratory Syncytial Virus (RSV), Human Parainfluenza Virus (HPIV), and Human Metapneumovirus (h

147 RSV, human metapneumovirus (HMPV), and human parainfluenza virus (HPIV), that have been reported in r

148 (23), human herpesvirus (HHV)-6B (10), human parainfluenza virus (HPIV)-2 (3), HPIV-3 (1), and human

149 he hemagglutinin-neuraminidase (HN) of human parainfluenza viruses (hPIV) in vitro and protected mice

150 Human parainfluenza viruses (HPIVs) are a common cause of acut

151 Human parainfluenza viruses (HPIVs) are among the most common

152 glutinin-neuraminidase (HN) protein of human parainfluenza viruses (hPIVs) both binds (H) and cleaves

153 Human parainfluenza viruses (HPIVs) cause widespread respirato

154 The first step in infection by human parainfluenza viruses (HPIVs) is binding to the surface

155 The paramyxoviruses, including human parainfluenza viruses (HPIVs), cause a large share of th

156 infected cells (Wake Forest strain of Canine parainfluenza virus) induced IL-8 secretion by a mechani

157 Analysis of parainfluenza virus infection in mice revealed an unexpe

158 We used mouse models of influenza and parainfluenza virus infection to show that intranasally

159 ccine nor clinically effective treatment for parainfluenza virus infection.

160 uenza virus, respiratory syncytial virus, or parainfluenza virus infection.

161 in mixed bone marrow chimeric mice during a parainfluenza virus infection.

162 central memory subpopulations to intranasal parainfluenza virus infection.

163 Parainfluenza virus infections did not differentially af

164 to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin

165 ools elicited by nonpersistent influenza and parainfluenza virus infections.

166 iratory syncytial virus, 2 adenovirus, and 1 parainfluenza virus infections.

167 ents with respiratory syncytial virus (RSV), parainfluenza virus, influenza virus, metapneumovirus (M

168 Parainfluenza viruses initiate infection by binding to c

169 t for lower-respiratory-tract infection with parainfluenza virus; it stabilized during the months aft

170 mouse model in which infection with a mouse parainfluenza virus known as Sendai virus (SeV) leads to

171 for RSV (n = 35), 2.6 x 10(6) copies/mL; for parainfluenza virus (n = 35), 4.9 x 10(7) copies/mL; for

172 Early childhood infection with parainfluenza virus or respiratory syncytial virus is st

173 nfluenza virus, respiratory syncytial virus, parainfluenza virus, or metapneumovirus, or a combinatio

174 rs mutations in the P/V gene from the canine parainfluenza virus (P/V-CPI(-)) is a potent inducer of

175 Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens

176 Parainfluenza virus (PIV) commonly infects patients foll

177 RSV F and related parainfluenza virus (PIV) F proteins are cleaved by furi

178 Parainfluenza virus (PIV) in humans is associated with b

179 Data on characteristics and outcomes of parainfluenza virus (PIV) infections in these patients a

180 Parainfluenza virus (PIV) is a cause of respiratory trac

181 Parainfluenza virus (PIV) is a leading cause of lower re

182 Parainfluenza virus (PIV) is a negative-sense single-str

183 s of virus transcription and replication for parainfluenza virus (PIV) type 2, PIV3, PIV5, and mumps

184 ually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3.

185 mens), followed by human rhinovirus (17.8%); parainfluenza virus (PIV) types 1-4 (7.5%); enterovirus

186 ith RSV and were given a boost with RSV or a parainfluenza virus (PIV) vector expressing RSV fusion p

187 sting for respiratory syncytial virus (RSV), parainfluenza virus (PIV), and influenza A and B, and by

188 yncytial virus (RSV), influenza virus (Flu), parainfluenza virus (PIV), human metapneumovirus (HMPV),

189 us (HRV), respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus (InfV), metap

190 (HN, residues 37 to 56) of the paramyxovirus parainfluenza virus (PIV5), a region of the HN stalk tha

191 Parainfluenza viruses (PIVs) are one of the most common

192 significance of membrane fusion activity in parainfluenza virus replication and pathogenesis in vivo

193 e (HN) glycoprotein plays a critical role in parainfluenza virus replication.

194 ruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial virus, huma

195 roviruses, influenza virus, metapneumovirus, parainfluenza virus, rhinovirus, and respiratory syncyti

196 The parainfluenza virus simian virus 5 (SV5) is a poor induc

197 Human epithelial cells infected with the parainfluenza virus simian virus 5 (SV5) show minimal ac

198 ediates the cellular entry of influenza, the parainfluenza virus, some enteroviruses and the bacteriu

199 aring the sequence of MV F with those of the parainfluenza virus SV5 and Newcastle disease virus (NDV

200 SER virus is a type 5 parainfluenza virus that does not exhibit syncytium form

201 eviously described heterotypic peptides from parainfluenza virus that potently inhibit Nipah virus in

202 Paramyxoviruses such as human parainfluenza viruses that bear inserts encoding protect

203 e protein or whole virus digests enables the parainfluenza virus to be identified and typed and for i

204 ew evidence regarding strategies employed by parainfluenza viruses to effectively circumvent respirat

205 ontact transmission, the predominant mode of parainfluenza virus transmission, was modeled accurately

206 n to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second re

207 Human parainfluenza virus type 1 (HPIV1) also causes severe pe

208 Sendai virus (SeV) and human parainfluenza virus type 1 (hPIV1) are highly similar in

209 We evaluated a version of human parainfluenza virus type 1 (HPIV1) bearing a stabilized

210 Sendai virus (SV) and human parainfluenza virus type 1 (hPIV1) have genomes consisti

211 Human parainfluenza virus type 1 (HPIV1) is a significant caus

212 Human parainfluenza virus type 1 (HPIV1) is a significant caus

213 Human parainfluenza virus type 1 (HPIV1) is an important respi

214 Human parainfluenza virus type 1 (HPIV1) is an important respi

215 respiratory syncytial virus (RSV) and human parainfluenza virus type 1 (HPIV1) to HPIV4 infect virtu

216 onkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced

217 valuation of an attenuated recombinant human parainfluenza virus type 1 (rHPIV1) expressing the membr

218 Live attenuated recombinant human parainfluenza virus type 1 (rHPIV1) was investigated as

219 Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to crea

220 ons of the L polymerase of recombinant human parainfluenza virus type 1 (rHPIV1).

221 live virus vaccine, we have used the murine parainfluenza virus type 1 (Sendai virus [SV]) as a xeno

222 Hamsters immunized with a recombinant human parainfluenza virus type 1 expressing the fusion F prote

223 Human parainfluenza virus type 1 is the major cause of croup i

224 secreted from A549 cells infected with Human parainfluenza virus type 2 (HPIV-2) but not from cells i

225 Human parainfluenza virus type 2 (HPIV-2), an important pediat

226 e-defective BC-PIV vector derived from human parainfluenza virus type 2 (hPIV2) by a reverse genetics

227 lication during infection of A549 cells with parainfluenza virus type 2 (PIV2), PIV3, PIV5, or mumps

228 t for association with V proteins from human parainfluenza virus type 2, parainfluenza virus type 5,

229 metapneumovirus (44%), rhinovirus (34%), and parainfluenza virus type 3 (28%); respiratory syncytial

230 domains with their counterparts from bovine parainfluenza virus type 3 (BPIV3) F protein to direct i

231 doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3).

232 Entry and fusion of human parainfluenza virus type 3 (HPF3) require the interactio

233 ur previous observation on the role of human parainfluenza virus type 3 (HPIV 3) C protein in the tra

234 The RNA polymerase complex of human parainfluenza virus type 3 (HPIV 3), a member of the fam

235 Paramyxovirus vaccine vectors based on human parainfluenza virus type 3 (HPIV-3) and Newcastle diseas

236 Human parainfluenza virus type 3 (hPIV-3) is a clinically sign

237 Human parainfluenza virus type 3 (HPIV-3) is an airborne patho

238 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric r

239 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agent

240 SV), human metapneumovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for t

241 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and sec

242 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes

243 The genomic promoter of human parainfluenza virus type 3 (HPIV3) contains multiple cis

244 genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

245 t also the receptor interaction of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

246 plementation to follow the dynamics of human parainfluenza virus type 3 (HPIV3) HN/F pairs in living

247 We demonstrate that human parainfluenza virus type 3 (HPIV3) induces incomplete au

248 onnected to the stalk region of either human parainfluenza virus type 3 (HPIV3) or Nipah virus recept

249 against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to expre

250 rt here that for three paramyxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of low

251 Human parainfluenza virus type 3 (HPIV3), a paramyxovirus, is

252 common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector

253 encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulat

254 ing the childhood respiratory pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope

255 For human parainfluenza virus type 3 (HPIV3), the effects of speci

256 For human parainfluenza virus type 3 (HPIV3), the receptor binding

257 aminidase (HN) surface glycoprotein of human parainfluenza virus type 3 (HPIV3).

258 intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3).

259 s), Newcastle disease virus (NDV), and human parainfluenza virus type 3 (HPIV3).

260 In this study, a chimeric bovine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human P

261 Parainfluenza virus type 3 (PIV3) infection led to laryn

262 Parainfluenza virus type 3 (PIV3) infections are a major

263 Parainfluenza virus type 3 (PIV3) is major pathogen of c

264 r the ability to inhibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negati

265 A live attenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion

266 or with a chimeric recombinant bovine/human parainfluenza virus type 3 (rB/HPIV3) vector expressing

267 we used an attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) vector to express

268 We used a chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) vector to express

269 A live attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed prev

270 We constructed a human recombinant parainfluenza virus type 3 (rPIV3) that expresses enhanc

271 For human parainfluenza virus type 3 and many other paramyxoviruse

272 tial innate antiviral response against human parainfluenza virus type 3 and respiratory syncytial vir

273 s virus of the Arenaviridae family and human parainfluenza virus type 3 of the Paramyxoviridae family

274 Human parainfluenza virus type 3, a mildly cytopathic virus th

275 yncytial virus, human metapneumovirus, human parainfluenza virus type 3, and measles virus, and highl

276 uses, including the childhood pathogen human parainfluenza virus type 3, enter host cells by fusion o

277 explores the binding and entry into cells of parainfluenza virus type 3, focusing on how the receptor

278 minidase abolished infection of HAE by human parainfluenza virus type 3, this treatment did not signi

279 vaccine for respiratory syncytial virus and parainfluenza virus type 3, two major causes of severe r

280 viruses, including the human pathogen human parainfluenza virus type 3, yet these compounds by thems

281 protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that express

282 ses to administration of a cocktail of human parainfluenza virus type 3-vectored vaccines against ind

283 Human parainfluenza virus type 3-vectored vaccines offer benef

284 lymphocytic choriomeningitis virus and human parainfluenza virus type 3.

285 ction of interferon (IFN) alpha/beta against parainfluenza virus type 5 (PIV5), selectively inhibitin

286 teins from human parainfluenza virus type 2, parainfluenza virus type 5, measles virus, mumps virus,

287 Paramyxoviruses such as human parainfluenza virus type-3 (HPIV3) and measles virus (Me

288 Similarly, F-glycoprotein trimers from human parainfluenza virus-type 3 and spike-glycoprotein trimer

289 We investigated the binding of human parainfluenza virus types 1 and 3 (hPIV1 and hPIV3, resp

290 luding influenza virus A, influenza virus B, parainfluenza virus types 1 and 3, respiratory syncytial

291 A and B and human metapneumovirus, and (iii) parainfluenza virus types 1 to 4.

292 virus (RSV), influenza virus type A (FluA), parainfluenza virus types 1, 2, and 3 (PIV1, PIV2, and P

293 iratory syncytial viruses A and B; and human parainfluenza virus types 1, 2, and 3.

294 3, B, respiratory syncytial virus, and human parainfluenza virus types 1-2 and 3), and develop a meth

295 iruses, including influenza A and B viruses, parainfluenza virus types 1-3, respiratory syncytial vir

296 ed negative for respiratory syncytial virus, parainfluenza viruses (types 1-3), influenza A and B vir

297 act of respiratory syncytial virus (RSV) and parainfluenza virus URIs on the frequency of AOM caused

298 C28a HN is the first parainfluenza virus variant found so far to be specifica

299 naturally occurring SV5 variant Wake Forest parainfluenza virus (WF-PIV) activates the synthesis of

300 so showed that extraction will be needed for parainfluenza virus, which was only identified correctly